Global Gene Therapy in Oncology Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Gene Therapy in Oncology Market Overview

• 1.1 Product Overview and Scope of Gene Therapy in Oncology
• 1.2 Classification of Gene Therapy in Oncology by Types
  • 1.2.1 Global Gene Therapy in Oncology Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Gene Therapy in Oncology Revenue Market Share by Types in 2018
  • 1.2.3 Ex Vivo
  • 1.2.4 In Vivo
• 1.3 Global Gene Therapy in Oncology Market by Application
  • 1.3.1 Global Gene Therapy in Oncology Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospitals
  • 1.3.3 Diagnostics Centers
  • 1.3.4 Research Institutes
• 1.4 Global Gene Therapy in Oncology Market by Regions
  • 1.4.1 Global Gene Therapy in Oncology Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Gene Therapy in Oncology Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy in Oncology Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy in Oncology Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy in Oncology Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy in Oncology Status and Prospect (2014-2024)
• 1.5 Global Market Size of Gene Therapy in Oncology (2014-2024)

2 Manufacturers Profiles

• 2.1 Bristol-Myers Squibb
  • 2.1.1 Business Overview
  • 2.1.2 Gene Therapy in Oncology Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Cold Genesys
  • 2.2.1 Business Overview
  • 2.2.2 Gene Therapy in Oncology Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Cold Genesys Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Advantagene
  • 2.3.1 Business Overview
  • 2.3.2 Gene Therapy in Oncology Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Advantagene Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Amgen
  • 2.4.1 Business Overview
  • 2.4.2 Gene Therapy in Oncology Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Amgen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 AstraZeneca
  • 2.5.1 Business Overview
  • 2.5.2 Gene Therapy in Oncology Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 AstraZeneca Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Bio-Path Holdings
  • 2.6.1 Business Overview
  • 2.6.2 Gene Therapy in Oncology Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Bio-Path Holdings Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 CRISPR Therapeutics
  • 2.7.1 Business Overview
  • 2.7.2 Gene Therapy in Oncology Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 CRISPR Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Editas Medicine
  • 2.8.1 Business Overview
  • 2.8.2 Gene Therapy in Oncology Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Editas Medicine Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Geron Corp
  • 2.9.1 Business Overview
  • 2.9.2 Gene Therapy in Oncology Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Geron Corp Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Idera Pharmaceuticals
  • 2.10.1 Business Overview
  • 2.10.2 Gene Therapy in Oncology Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Intellia Therapeutics
  • 2.11.1 Business Overview
  • 2.11.2 Gene Therapy in Oncology Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Intellia Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Johnson & Johnson
  • 2.12.1 Business Overview
  • 2.12.2 Gene Therapy in Oncology Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Johnson & Johnson Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Marsala Biotech
  • 2.13.1 Business Overview
  • 2.13.2 Gene Therapy in Oncology Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Marsala Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Merck
  • 2.14.1 Business Overview
  • 2.14.2 Gene Therapy in Oncology Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Merck Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Mologen AG
  • 2.15.1 Business Overview
  • 2.15.2 Gene Therapy in Oncology Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Mologen AG Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Oncolytics Biotech
  • 2.16.1 Business Overview
  • 2.16.2 Gene Therapy in Oncology Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Oncolytics Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Oncosec
  • 2.17.1 Business Overview
  • 2.17.2 Gene Therapy in Oncology Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Oncosec Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Oncotelic
  • 2.18.1 Business Overview
  • 2.18.2 Gene Therapy in Oncology Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Oncotelic Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Shenzhen SiBiono GeneTech
  • 2.19.1 Business Overview
  • 2.19.2 Gene Therapy in Oncology Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Sillajen Biotherapeutics
  • 2.20.1 Business Overview
  • 2.20.2 Gene Therapy in Oncology Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Tocagen
  • 2.21.1 Business Overview
  • 2.2.2 Gene Therapy in Oncology Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Tocagen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 UniQure
  • 2.22.1 Business Overview
  • 2.22.2 Gene Therapy in Oncology Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 UniQure Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 Ziopharm Oncology
  • 2.23.1 Business Overview
  • 2.23.2 Gene Therapy in Oncology Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 Ziopharm Oncology Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)

3 Global Gene Therapy in Oncology Market Competition, by Players

• 3.1 Global Gene Therapy in Oncology Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Gene Therapy in Oncology Players Market Share
  • 3.2.2 Top 10 Gene Therapy in Oncology Players Market Share
• 3.3 Market Competition Trend

4 Global Gene Therapy in Oncology Market Size by Regions

• 4.1 Global Gene Therapy in Oncology Revenue and Market Share by Regions
• 4.2 North America Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 4.3 Europe Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 4.5 South America Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

5 North America Gene Therapy in Oncology Revenue by Countries

• 5.1 North America Gene Therapy in Oncology Revenue by Countries (2014-2019)
• 5.2 USA Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 5.3 Canada Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

6 Europe Gene Therapy in Oncology Revenue by Countries

• 6.1 Europe Gene Therapy in Oncology Revenue by Countries (2014-2019)
• 6.2 Germany Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 6.3 UK Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 6.4 France Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 6.5 Russia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 6.6 Italy Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Gene Therapy in Oncology Revenue by Countries

• 7.1 Asia-Pacific Gene Therapy in Oncology Revenue by Countries (2014-2019)
• 7.2 China Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 7.3 Japan Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 7.4 Korea Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 7.5 India Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

8 South America Gene Therapy in Oncology Revenue by Countries

• 8.1 South America Gene Therapy in Oncology Revenue by Countries (2014-2019)
• 8.2 Brazil Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Gene Therapy in Oncology by Countries

• 9.1 Middle East and Africa Gene Therapy in Oncology Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 9.3 UAE Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

10 Global Gene Therapy in Oncology Market Segment by Type

• 10.1 Global Gene Therapy in Oncology Revenue and Market Share by Type (2014-2019)
• 10.2 Global Gene Therapy in Oncology Market Forecast by Type (2019-2024)
• 10.3 Ex Vivo Revenue Growth Rate (2014-2024)
• 10.4 In Vivo Revenue Growth Rate (2014-2024)

11 Global Gene Therapy in Oncology Market Segment by Application

• 11.1 Global Gene Therapy in Oncology Revenue Market Share by Application (2014-2019)
• 11.2 Gene Therapy in Oncology Market Forecast by Application (2019-2024)
• 11.3 Hospitals Revenue Growth (2014-2019)
• 11.4 Diagnostics Centers Revenue Growth (2014-2019)
• 11.5 Research Institutes Revenue Growth (2014-2019)

12 Global Gene Therapy in Oncology Market Size Forecast (2019-2024)

• 12.1 Global Gene Therapy in Oncology Market Size Forecast (2019-2024)
• 12.2 Global Gene Therapy in Oncology Market Forecast by Regions (2019-2024)
• 12.3 North America Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
• 12.4 Europe Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
• 12.6 South America Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Gene Therapy in Oncology Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology